Why early regulatory involvement accelerates medical device and IVD innovation

Medical device and in vitro diagnostic (IVD) innovation requires close collaboration between research and development, clinical, quality, manufacturing, marketing and regulatory functions, which each see the product from a different perspective. Regulatory affairs connects these perspectives to the expectations of authorities, notified bodies, standards and market access requirements. Yet, regulatory expertise often enters the conversation later, when the product concept is already mature and the team is preparing for market entry.

Involving regulatory affairs earlier helps teams make better design decisions, identify evidence needs sooner and avoid costly rework and delays due to redesign, relabelling, revised evidence plans and new timelines. Instead of slowing innovation down, early regulatory involvement helps teams move faster because they move in the right direction from the beginning. Thus, regulatory thinking is not a final checkpoint, but one of the most powerful accelerators of responsible and cost-effective innovation.

This is where Medfiles can support medical device and IVD manufacturers. Combining quality, regulatory and clinical expertise enables support from early regulatory strategy and evidence planning to clinical investigations, performance studies and market access. Bringing these perspectives together early helps manufacturers make better development decisions, identify evidence needs sooner and build a clearer path from product concept to compliant market access.

Early regulatory strategy reduces rework

Every medical device and IVD concept needs to answer fundamental questions that determine the regulatory pathway: What is the intended use and purpose, intended target population and intended user? What is the mode of action and which claims will be made? Which risk classification applies and what is the appropriate conformity assessment route? What evidence is needed to demonstrate safety and performance throughout the product lifecycle? What risks are associated with the device and how will they be mitigated?

The intended use/purpose and mode of action are the most important factors influencing whether a product qualifies as a medical device or IVD and which classification rules apply. Defining them as soon as the product concept is sufficiently understood also establishes the foundation for the device’s claims, target population, users and clinical context. An early, well-justified risk classification also clarifies the applicable conformity assessment route and the expected level of technical and clinical evidence, allowing these requirements to be incorporated into the design and development plan before costly commitments are made.

Many delays in medical device and IVD development are not caused by lack of innovation, but by late discovery of regulatory requirements. An unclear intended purpose, insufficient risk management documentation or weak traceability between requirements and verification can lead to redesign, additional testing and delayed market entry. As product claims, clinical evaluation, risk management and post-market surveillance are tightly interlinked, the claims made early in the project need to guide the clinical evidence strategy. Later changes may require new evidence, introduce new risks or alter the planned post-market actions. Making these connections visible early supports stronger design controls, clearer documentation, more efficient decisions and a more cost-effective development process with fewer surprises.

Combining regulatory and clinical expertise supports better evidence planning

Evidence generation is often one of the longest and most resource-intensive parts of medical device and IVD development. For innovative devices, especially those involving new technologies, software, artificial intelligence or novel clinical workflows, the evidence expectations may not be straightforward. Early regulatory input helps teams define what evidence is needed, when it should be generated and how it should be documented. This may include performance testing, usability engineering, biological safety, cybersecurity, software validation, clinical evaluation or post-market clinical follow-up planning. Teams should also establish early whether clinical evidence can be drawn from pre-clinical testing, scientific literature and other available knowledge or whether clinical studies are needed. The earlier these needs are understood, the easier it is to integrate them into the development timeline.

If a clinical investigation or performance study is required, regulatory and clinical expertise become particularly closely connected. Study objectives, endpoints, target population and evidence requirements need to be aligned with the intended purpose and overall development strategy from the outset to assure regulatory alignment. This proactive approach also aligns closely with the expectations of clinical research guidelines ISO 14155:2026, ISO 20916:2019 and ICH GCP E6(R3) and E8(R1), which emphasise, in addition to participant safety and wellbeing, the importance of data integrity and scientific quality for the intended purpose as part of continuous risk-benefit assessment of study justification.

When in-house expertise is limited, engaging an experienced contract research organisation (CRO) like Medfiles can further strengthen this process. By combining expertise in clinical research, regulatory affairs and Good Clinical Practice, Medfiles helps translate regulatory and evidence requirements into a practical study strategy, reducing uncertainty and helping manufacturers avoid costly delays and rework.

How Medfiles can support clinical investigations and performance studies

Medfiles can support a manufacturer with individual study activities or manage the entire clinical investigation or performance study from planning to the final clinical study report. During study planning, support may include protocol development, feasibility assessments, investigator and site selection, regulatory and ethics submissions, and the establishment of the operational systems needed to run the study. This includes coordinating data collection processes, vendor and laboratory activities, study supplies and document management, while ensuring that the study objectives, endpoints and target population are aligned with the intended purpose and evidence requirements of the device.

Once the study is underway, a CRO acts as the operational hub connecting the sponsor, sites, laboratories and other service providers. CRO support may include project management, site training, risk-based monitoring, safety reporting, data management and oversight of essential study documentation. Continuous oversight helps ensure that all stakeholders remain informed, study records remain inspection-ready and regulatory requirements are met throughout the project.

An important benefit of CRO involvement is proactive risk management. Identifying potential issues early allows mitigation measures to be implemented before they compromise study quality, evidence generation or timelines. For example, a CRO may identify slow recruitment at an early stage and implement mitigation measures before study timelines are affected. It may detect protocol deviations through ongoing monitoring and provide additional site training to prevent recurring issues. A CRO can also anticipate risks related to missing data, delayed laboratory analyses, investigational product supply, vendor performance or regulatory submissions. Addressing these issues before they compromise study quality, timelines or evidence generation helps protect participants while ensuring that study data remains complete, traceable and suitable for clinical or performance evaluation.

At study close-out, a CRO can coordinate site closure, database lock, statistical analysis, documentation reconciliation and preparation of the clinical study report. End-to-end involvement reduces handover gaps, supports evidence quality and provides a cost-effective path to generating the robust clinical evidence needed for regulatory decision-making and market access.

The benefits of choosing Medfiles as a regulatory and CRO partner

With regulatory and CRO expertise within the same partner, medical device and IVD manufacturers can connect regulatory strategy, evidence planning and clinical study execution throughout the product development pathway.

Medfiles supports medical device and IVD innovators from early development through market entry and post-market activities. Our team has over a decade of experience in medical device clinical investigations and IVD performance studies as well as medical device and IVD regulatory affairs.

Regulatory support can include aligning the intended purpose, claims, classification and evidence strategy, as well as the preparation of technical documentation. When a clinical investigation or performance study is needed, CRO support can cover study planning, documentation and coordination through study conduct, close-out and reporting.

Medfiles’ support also extends to vigilance reporting and post-market follow-up. Aligning clinical/performance evaluation, risk management, vigilance and post-market surveillance planning early in the project helps reduce uncertainty, avoid unnecessary rework and ensure that these activities support the same regulatory and development strategy.

Here is how our clients describe working with Medfiles:

Author: Emma Talvitie 
Regulatory Affairs Expert, Medical Devices and IVDs  

Emma Talvitie is a medical device and in vitro diagnostic (IVD) regulatory affairs professional with a Master of Science (Tech.) degree in biotechnology, who has over 5 years of professional experience in MD and IVD regulatory affairs. Emma has a strong background in IVD regulatory affairs and assay development. During her studies she focused on assay development, especially in molecular diagnostics and immunoassays. She started her career by updating the IVDD compliant technical documentation of an IVD analyser to be compliant with the IVDR. She has also been responsible for planning, executing, data analysis and reporting of IVD assay verification and validation studies and contributed to writing and reviewing IVDR and FDA 510(k) documentation for IVD assays.

Since April 2023, as a Regulatory Affairs Expert at Medfiles, Emma has worked in varying projects helping clients with regulatory issues and compiling technical documentation for multiple medical devices and IVDs. Emma is exited about contributing to the development of innovative, high-quality devices that meet both regulatory requirements and user needs.

Author: Anna Lyra
Senior Clinical Research Associate  

Anna Lyra is a Senior Clinical Research Associate at Medfiles with a Ph.D. in Microbiology and over 15 years of experience in clinical research, clinical study management and scientific research. Her experience spans medical device, IVD, medicinal product and nutrition studies, with expertise in clinical study planning, protocol and Clinical Investigation Plan development, monitoring, site management, regulatory submissions and clinical study reporting. Anna has contributed to numerous clinical studies and investigations in roles ranging from study coordinator and monitor to project manager and clinical study manager. She is passionate about helping innovators generate high-quality clinical evidence for translating scientific innovation into safe, effective and compliant healthcare solutions.